Induction of differentiation of leukaemic (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates apoptosis triggered by onconase.
Onconase (Onc) is a ribonuclease from amphibian oocytes that is cytostatic and cytotoxic to many tumour lines. It shows in vivo antitumour activity in mouse tumour models and is currently in Phase III clinical trials. The present study was designed to test whether cytotoxic effects of ONC can be modulated by differentiating agents. Human leukaemic HL-60 and prostate cancer LNCaP and JCA-1 cells were treated with Onc in the absence and presence of several inducers of differentiation and frequency of apoptosis was assessed using three different cytometric methods and confirmed by analysis of cell morphology. A moderate degree of apoptosis observed after 48-72 h incubation of HL-60 cells in the presence of 0.42 microM Onc alone was markedly potentiated by administration of retinoic acid (all trans), sodium butyrate or dimethylsulfoxide at concentrations known to induce differentiation but be minimally cytotoxic. Likewise, the frequency of apoptosis of LNCaP and JCA-1 cells treated with Onc was increased in the cultures to which phenylbutyrate was added. Although cell treatment with Onc alone, with each of the differentiating agents alone or with Onc in combination with the differentiating agents led to an increase in the proportion of G1 cells, no specific cell cycle phase preference in induction of apoptosis was observed. The data suggest that cells undergoing differentiation are particularly vulnerable to Onc; a combination of Onc and differentiating agents should be considered for further in vivo tests to assess its possible usefulness in the clinic.
Halicka
H D
HD
Brander Cancer Research Institute, New York Medical College, Valhalla, USA.
Murakami
T
T
Papageorgio
C N
CN
Mittelman
A
A
Mikulski
S M
SM
Shogen
K
K
Darzynkiewicz
Z
Z
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D002087:Butyrates / Q000494:pharmacology; D002454:Cell Differentiation; D004247:DNA / Q000378:metabolism; D004121:Dimethyl Sulfoxide / Q000494:pharmacology; D004357:Drug Synergism; D004527:Egg Proteins / Q000494:pharmacology*; D018922:HL-60 Cells; D006801:Humans; D008297:Male; D010654:Phenylbutyrates / Q000494:pharmacology; D011471:Prostatic Neoplasms; D012313:RNA / Q000378:metabolism; D012260:Ribonucleases / Q000494:pharmacology*; D014212:Tretinoin / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D002087:Butyrates; D004527:Egg Proteins; D010654:Phenylbutyrates; D014212:Tretinoin; D012313:RNA; D004247:DNA; D012260:Ribonucleases; D004121:Dimethyl Sulfoxide; C058703:ranpirnase